OncoGenex’s OGX-427 drug gaining investor attention
Even though OncoGenex Pharmaceuticals (NASDAQ:OGXI) and its pivotal programs with lead oncology candidate, custirsen, are being closely followed, investors are beginning to notice the company’s second...
View ArticleOncoGenex Phase 3 prostate cancer trial fails
Top-line survival results of OncoGenex Pharmaceuticals’ (NASDAQ:OGXI) Phase 3 SYNERGY trial indicate that the addition of custirsen to standard first-line docetaxel/prednisone therapy did not meet the...
View Article
More Pages to Explore .....